Komatsu, Shun-ichiro
Kayukawa, Yoko
Miyazaki, Yoko
Kaneko, Akihisa
Ikegami, Hisashi
Ishiguro, Takahiro
Nakamura, Mikiko
Frings, Werner
Ono, Natsuki
Sakata, Kiyoaki
Fujii, Toshihiko
Kishishita, Shohei
Kitazawa, Takehisa
Endo, Mika
Sano, Yuji http://orcid.org/0000-0003-3714-4983
Clinical trials referenced in this document:
Documents that mention this clinical trial
Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial
https://doi.org/10.1038/s41598-022-16564-x
Funding for this research was provided by:
Chugai Pharm
Article History
Received: 19 January 2022
Accepted: 12 July 2022
First Online: 19 July 2022
Competing interests
: All authors are employees of Chugai Pharmaceutical Co., Ltd., and Chugai Pharmaceutical Co., Ltd. is involved in the research and development of medicines. This study was funded by Chugai Pharmaceutical Co., Ltd.